# A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

> **NCT06208150** · PHASE3 · RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 795 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Talquetamab
- **DRUG:** Pomalidomide
- **DRUG:** Teclistamab
- **DRUG:** Elotuzumab
- **DRUG:** Dexamethasone
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT06208150
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-22
- **Primary completion:** 2026-04-23
- **Final completion:** 2028-03-31
- **Target enrollment:** 795 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06208150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06208150, "A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06208150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*